Boston Court Reinstates Neurontin Class-Action Lawsuit

Kermit Cole
0
55

Pfizer may face lawsuits regarding improper marketing of Neurontin after a Boston court reinstated lawsuits that had been denied class-action status by lower courts. The court also upheld a $142.1 million award against Pfizer for damages related to the marketing of Neurontin.

Article →

Of further interest:
Court upholds $142 mln verdict against Pfizer over Neurontin (Reuters)
Pfizer fails to block $142M Neurontin award, faces 2 more suits (Fierce Pharma)

Previous articleFive Key Fantasies Embraced by the DSM
Next article“Talk Doesn’t Pay, So Psychiatry Turns Instead to Drug Therapy”
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]

LEAVE A REPLY